Eli Lilly’s clinical trial of the experimental drug donanemab appears to have successfully slowed cognitive decline in patients with the early symptoms of Alzheimer’s. The TRAILBLAZER-ALZ clinical trial was a …
Larger Clinical Trial for Alzheimer’s Drug Donanemab Starting Soon Read More »
If you or a loved one are experiencing signs of early Alzheimer’s disease, there may soon be treatment and hope on the horizon. First Choice Neurology is participating in an …
BAN2401 Study to Assess New Alzheimer’s Treatment Read More »
Biogen is planning to file for U.S. regulatory approval for its Alzheimer’s treatment aducanumab after data from more patients in two discontinued studies showed that the drug improved cognition at …
Biogen Seeks FDA Approval for New Alzheimer’s Drug Read More »
